C Max Schmidt Selected Research

Pancreaticojejunostomy

2/2016	Pancreaticojejunostomy Stricture After Pancreatoduodenectomy: Outcomes After Operative Revision.
5/2009	Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

C Max Schmidt Research Topics

Disease

44	Neoplasms (Cancer) 08/2023 - 04/2002
34	Pancreatic Neoplasms (Pancreatic Cancer) 08/2023 - 04/2002
18	Neoplasms, Cystic, Mucinous, and Serous 02/2021 - 05/2010
17	Adenocarcinoma 01/2023 - 07/2004
15	Pancreatic Cyst 11/2022 - 02/2008
14	Cysts 11/2022 - 02/2004
11	Pancreatic Fistula (Pancreatic Fistulas) 11/2023 - 12/2007
9	Hepatocellular Carcinoma (Hepatoma) 04/2010 - 12/2003
8	Pancreatitis 01/2022 - 10/2014
6	Infections 01/2022 - 05/2013
6	Carcinogenesis 01/2021 - 04/2005
4	Pain (Aches) 01/2022 - 04/2002
4	Chronic Pancreatitis 01/2021 - 10/2011
4	Necrosis 01/2021 - 12/2009
4	Neoplasm Metastasis (Metastasis) 04/2013 - 04/2008
3	Margins of Excision 10/2022 - 05/2009
3	Weight Loss (Weight Reduction) 01/2022 - 10/2014
2	Sphincter of Oddi Dysfunction 12/2023 - 01/2019
2	Jaundice (Icterus) 01/2022 - 06/2003
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 10/2018
2	Pulmonary Embolism 01/2021 - 01/2019
2	Pathologic Constriction (Stenosis) 01/2021 - 02/2016
2	Acute Necrotizing Pancreatitis 01/2021 - 12/2009
2	Surgical Wound Infection 10/2019 - 10/2018
2	Primitive Neuroectodermal Tumors (PNET) 03/2019 - 05/2009
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 01/2019
2	Wound Infection (Wound Infections) 01/2019 - 01/2009
2	Inflammation (Inflammations) 10/2014 - 04/2009
2	Abdominal Abscess 04/2014 - 01/2009
2	Hepatitis 08/2009 - 06/2009
1	Myocardial Infarction 11/2023
1	Thrombosis (Thrombus) 10/2022
1	Sepsis (Septicemia) 10/2022
1	Urinary Retention 01/2022

Drug/Important Bio-Agent (IBA)

13	Biomarkers (Surrogate Marker)IBA 02/2021 - 01/2008
10	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 04/2010 - 11/2003
9	Proteins (Proteins, Gene)FDA Link 02/2021 - 06/2007
8	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 11/2003
6	NF-kappa B (NF-kB)IBA 04/2013 - 04/2005
6	Sulindac (Copal)FDA LinkGeneric 11/2009 - 03/2003
5	Carcinoembryonic AntigenIBA 01/2021 - 04/2007
5	Gemcitabine FDA Link 10/2015 - 02/2008
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2021 - 04/2014
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 06/2003
4	Amylases FDA Link 01/2021 - 12/2011
4	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 10/2017 - 03/2003
4	parthenolideIBA 12/2013 - 04/2005
4	Transcription Factors (Transcription Factor)IBA 04/2013 - 04/2005
4	CarcinogensIBA 11/2009 - 06/2006
3	Tumor Biomarkers (Tumor Markers)IBA 11/2022 - 06/2003
3	EnzymesIBA 01/2022 - 10/2014
3	MucinsIBA 01/2021 - 02/2004
3	Secretin FDA Link 08/2020 - 03/2012
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2019
3	Dinoprostone (PGE2)FDA Link 01/2019 - 06/2006
3	Indicators and Reagents (Reagents)IBA 10/2018 - 02/2008
3	U 0126 (UO 126)IBA 06/2009 - 11/2003
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 10/2008 - 12/2003
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2007 - 12/2003
2	MicroRNAs (MicroRNA)IBA 01/2023 - 10/2016
2	VaccinesIBA 01/2022 - 01/2020
2	Lipase (Acid Lipase)FDA Link 01/2021 - 10/2014
2	CA-19-9 Antigen (CA 19-9 Antigen)IBA 01/2019 - 04/2007
2	CarbohydratesIBA 01/2019 - 04/2007
2	ProinsulinIBA 01/2019 - 01/2019
2	Glycoproteins (Glycoprotein)IBA 01/2019 - 07/2012
2	Circulating Tumor DNAIBA 01/2017 - 02/2014
2	Alkaline PhosphataseIBA 10/2014 - 06/2003
2	Polysaccharides (Glycans)IBA 07/2012 - 05/2010
2	LC-1 compoundIBA 07/2012 - 10/2008
2	mirdametinibIBA 04/2010 - 01/2008
2	Transforming Growth Factor alpha (TGF-alpha)IBA 06/2009 - 01/2008
2	2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluoro- 5- bromobenzamideIBA 06/2009 - 01/2006
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2009 - 12/2008
2	Mitogen-Activated Protein KinasesIBA 06/2009 - 03/2004
2	Celecoxib (Celebrex)FDA Link 10/2008 - 11/2007
2	ProstaglandinsIBA 02/2008 - 11/2007
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 06/2007 - 06/2006
1	tyramine-deoxysorbitolIBA 12/2023
1	Sulfoglycosphingolipids (Sulfatides)IBA 08/2023
1	CeramidesIBA 08/2023
1	Galactosylceramides (Galactocerebrosides)IBA 08/2023

Therapy/Procedure

15	Therapeutics 04/2020 - 03/2003
14	Pancreatectomy 10/2022 - 10/2007
14	Pancreaticoduodenectomy 01/2021 - 10/2007
12	Drug Therapy (Chemotherapy) 01/2023 - 06/2006
10	Length of Stay 01/2022 - 12/2007
4	Debridement 01/2022 - 12/2009
3	Neoadjuvant Therapy 01/2023 - 10/2011
3	Operative Time 01/2021 - 07/2010
3	Splenectomy 01/2020 - 04/2010
3	Chemoprevention 04/2013 - 01/2008
3	Radiotherapy 01/2011 - 04/2008
2	Catheters 01/2022 - 10/2018
2	Patient Readmission 01/2021 - 05/2013
2	Gastrostomy 12/2020 - 01/2019
2	Pancreaticojejunostomy 02/2016 - 05/2009
1	Endoscopic Sphincterotomy 12/2023
1	Transduodenal Sphincterotomy 12/2023
1	Blood Transfusion (Blood Transfusions) 11/2023